Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2019 Filed Feb 28, 2019 16:17 UTC |
DUFFY MICHAEL PSee Remarks
|
SaleCommon Stock | 2,360 | $23.17 | $54,681.20 |
DisclosureSEC source: 0000899243-19-005217 · doc4.xml · nonDerivative · entry 2 DUFFY MICHAEL P · CIK 0001237200 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,010 F1 · kind: Starting in 2019, the Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions under 10b5-1 plans. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018, to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 21:15 UTC |
Orlandi CesareChief Medical Officer
|
SaleCommon Stock | 3,111 | $23.10 | $71,870.32 |
DisclosureSEC source: 0000899243-19-005210 · doc4.xml · nonDerivative · entry 2 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,004 F1 · kind: Starting in 2019, the Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions under 10b5-1 plans. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018, to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.56 to $23.62, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 21:16 UTC |
Heino Mary AnneDirector · President & CEO
|
GrantCommon Stock | 88,169 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005006 · doc4.xml · nonDerivative · entry 2 Heino Mary Anne · CIK 0001610676 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 709,495 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 16:21 UTC |
SCHAFFER DERACE LDirector
|
GrantCommon Stock | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005223 · doc4.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,994 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 16:15 UTC |
Pruden Gary JDirector
|
GrantCommon Stock | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005208 · doc4.xml · nonDerivative · entry 1 Pruden Gary J · CIK 0001673416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,264 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:16 UTC |
McHugh JulieDirector
|
GrantCommon Stock | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005215 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,105 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:15 UTC |
Clemmer James CDirector
|
GrantCommon Stock | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005209 · doc4.xml · nonDerivative · entry 1 Clemmer James C · CIK 0001476700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,987 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 16:18 UTC |
Thrall James HDirector
|
GrantCommon Stock | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005220 · doc4.xml · nonDerivative · entry 1 Thrall James H · CIK 0001315048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,264 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 16:15 UTC |
MARKISON BRIAN ADirector
|
GrantCommon Stock | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005207 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,467 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 16:16 UTC |
LENO SAM RDirector
|
GrantCommon Stock | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005214 · doc4.xml · nonDerivative · entry 1 LENO SAM R · CIK 0001238660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,530 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 16:17 UTC |
DUFFY MICHAEL PSee Remarks
|
GrantCommon Stock | 20,044 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005217 · doc4.xml · nonDerivative · entry 1 DUFFY MICHAEL P · CIK 0001237200 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,370 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 16:16 UTC |
Pucel KennethDirector
|
GrantCommon Stock | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005213 · doc4.xml · nonDerivative · entry 1 Pucel Kenneth · CIK 0001312691 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,264 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 16:24 UTC |
Robertson A FrederickDirector
|
GrantCommon Stock | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005227 · doc4.xml · nonDerivative · entry 1 Robertson A Frederick · CIK 0001396084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,994 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:17 UTC |
Marshall Robert J. Jr.CFO and Treasurer
|
GrantCommon Stock | 19,946 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005218 · doc4.xml · nonDerivative · entry 1 Marshall Robert J. Jr. · CIK 0001754976 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,588 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:16 UTC |
Bolla John J.See Remarks
|
GrantCommon Stock | 16,154 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005216 · doc4.xml · nonDerivative · entry 1 Bolla John J. · CIK 0001741843 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,774 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:15 UTC |
Orlandi CesareChief Medical Officer
|
GrantCommon Stock | 13,426 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005210 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,115 Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 21:16 UTC |
Heino Mary AnneDirector · President & CEO
|
SaleCommon Stock | 9,456 | $24.06 | $227,518.92 |
DisclosureSEC source: 0000899243-19-005006 · doc4.xml · nonDerivative · entry 1 Heino Mary Anne · CIK 0001610676 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 621,326 F1 · kind: Starting in 2019, the Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions under 10b5-1 plans. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018, to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.60 to $24.28, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:30 UTC |
Orlandi CesareChief Medical Officer
|
SaleCommon Stock | 4,057 | $18.06 | $73,269.42 |
DisclosureSEC source: 0000899243-19-003034 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,689 F1 · kind: The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 16:30 UTC |
DUFFY MICHAEL PSee Remarks
|
SaleCommon Stock | 7,651 | $16.48 | $126,088.48 |
DisclosureSEC source: 0000899243-19-002317 · doc4.xml · nonDerivative · entry 1 DUFFY MICHAEL P · CIK 0001237200 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,326 F1 · kind: Starting in 2019, the Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions under 10b5-1 plans. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018, to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 21:30 UTC |
Orlandi CesareChief Medical Officer
|
SaleCommon Stock | 3,060 | $16.56 | $50,676.66 |
DisclosureSEC source: 0000899243-19-002316 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,746 F1 · kind: Starting in 2019, the Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions under 10b5-1 plans. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018, to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.31 to $16.82, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 21:30 UTC |
Heino Mary AnneDirector · President & CEO
|
SaleCommon Stock | 9,564 | $16.47 | $157,497.08 |
DisclosureSEC source: 0000899243-19-002318 · doc4.xml · nonDerivative · entry 1 Heino Mary Anne · CIK 0001610676 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,782 F1 · kind: Starting in 2019, the Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions under 10b5-1 plans. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018, to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.31 to $16.66, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 21:30 UTC |
Orlandi CesareChief Medical Officer
|
SaleCommon Stock | 4,058 | $18.02 | $73,125.16 |
DisclosureSEC source: 0000899243-18-029950 · doc4.xml · nonDerivative · entry 4 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,806 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 21:30 UTC |
Orlandi CesareChief Medical Officer
|
SaleCommon Stock | 800 | $18.00 | $14,400.00 |
DisclosureSEC source: 0000899243-18-029950 · doc4.xml · nonDerivative · entry 3 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,864 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 21:30 UTC |
Orlandi CesareChief Medical Officer
|
SaleCommon Stock | 400 | $18.01 | $7,204.00 |
DisclosureSEC source: 0000899243-18-029950 · doc4.xml · nonDerivative · entry 2 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,664 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 21:30 UTC |
Orlandi CesareChief Medical Officer
|
SaleCommon Stock | 1,797 | $18.00 | $32,346.00 |
DisclosureSEC source: 0000899243-18-029950 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,064 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:30 UTC |
Marshall Robert J. Jr.CFO and Treasurer
|
GrantCommon Stock | 44,642 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-026867 · doc4.xml · nonDerivative · entry 1 Marshall Robert J. Jr. · CIK 0001754976 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,642 Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 16:30 UTC |
DUFFY MICHAEL PSee Remarks
|
Tax withholdingCommon Stock | 5,501 | $15.55 | $85,540.55 |
DisclosureSEC source: 0000899243-18-023848 · doc4.xml · nonDerivative · entry 1 DUFFY MICHAEL P · CIK 0001237200 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,977 F1 · kind: The transaction reported on this Form 4 represents the disposition of shares withheld by the Company to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 20:30 UTC |
Orlandi CesareChief Medical Officer
|
Tax withholdingCommon Stock | 2,945 | $15.55 | $45,794.75 |
DisclosureSEC source: 0000899243-18-023847 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,861 F1 · kind: The transaction reported on this Form 4 represents the disposition of shares withheld by the Company to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 20:31 UTC |
Heino Mary AnneDirector · President & CEO
|
Tax withholdingCommon Stock | 9,699 | $16.10 | $156,153.90 |
DisclosureSEC source: 0000899243-18-023849 · doc4.xml · nonDerivative · entry 1 Heino Mary Anne · CIK 0001610676 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,346 F1 · kind: The transaction reported on this Form 4 represents the disposition of shares withheld by the Company to satisfy withholding tax liabilities of the Reporting Person associated with the initial vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 21:06 UTC |
McHugh JulieDirector
|
SaleCommon Stock | 4,560 | $14.72 | $67,123.20 |
DisclosureSEC source: 0000899243-18-018348 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,752 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.55 to $15.00, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 20:14 UTC |
Bolla John J.See Remarks
|
GrantCommon Stock | 22,620 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017167 · doc4.xml · nonDerivative · entry 1 Bolla John J. · CIK 0001741843 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,620 Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:30 UTC |
Orlandi CesareChief Medical Officer
|
SaleCommon Stock | 716 | $18.00 | $12,888.00 |
DisclosureSEC source: 0000899243-18-011289 · doc4.xml · nonDerivative · entry 2 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,806 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:30 UTC |
Orlandi CesareChief Medical Officer
|
SaleCommon Stock | 3,794 | $18.05 | $68,481.70 |
DisclosureSEC source: 0000899243-18-011289 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,522 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| April 30, 2018 Filed May 1, 2018 21:14 UTC |
Orlandi CesareChief Medical Officer
|
SaleCommon Stock | 600 | $18.00 | $10,800.00 |
DisclosureSEC source: 0000899243-18-011028 · doc4.xml · nonDerivative · entry 3 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,316 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| April 27, 2018 Filed May 1, 2018 21:14 UTC |
Orlandi CesareChief Medical Officer
|
SaleCommon Stock | 1,300 | $18.03 | $23,439.00 |
DisclosureSEC source: 0000899243-18-011028 · doc4.xml · nonDerivative · entry 2 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,916 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| April 27, 2018 Filed May 1, 2018 21:14 UTC |
Orlandi CesareChief Medical Officer
|
SaleCommon Stock | 6,901 | $18.00 | $124,218.00 |
DisclosureSEC source: 0000899243-18-011028 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,216 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 16:10 UTC |
DUFFY MICHAEL PSee Remarks
|
Tax withholdingCommon Stock | 6,681 | $17.90 | $119,589.90 |
DisclosureSEC source: 0000899243-18-010878 · doc4.xml · nonDerivative · entry 1 DUFFY MICHAEL P · CIK 0001237200 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,478 F1 · kind: The transaction reported on this Form 4 represents the disposition of shares withheld by the Company to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:10 UTC | Tax withholdingCommon Stock | 4,565 | $17.90 | $81,713.50 |
DisclosureSEC source: 0000899243-18-010880 · doc4.xml · nonDerivative · entry 1 Crowley John W. · CIK 0001610665 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,825 F1 · kind: The transaction reported on this Form 4 represents the disposition of shares withheld by the Company to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
|
| April 26, 2018 Filed Apr 27, 2018 20:10 UTC |
Orlandi CesareChief Medical Officer
|
SaleCommon Stock | 4,194 | $18.00 | $75,492.00 |
DisclosureSEC source: 0000899243-18-010879 · doc4.xml · nonDerivative · entry 2 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,117 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2017. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:10 UTC |
Orlandi CesareChief Medical Officer
|
Tax withholdingCommon Stock | 3,314 | $17.90 | $59,320.60 |
DisclosureSEC source: 0000899243-18-010879 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,311 F1 · kind: The transaction reported on this Form 4 represents the disposition of shares withheld by the Company to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:10 UTC |
Heino Mary AnneDirector · President & CEO
|
Tax withholdingCommon Stock | 29,449 | $17.90 | $527,137.10 |
DisclosureSEC source: 0000899243-18-010877 · doc4.xml · nonDerivative · entry 1 Heino Mary Anne · CIK 0001610676 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,045 F1 · kind: The transaction reported on this Form 4 represents the disposition of shares withheld by the Company to satisfy withholding tax liabilities of the Reporting Person associated with the initial vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:23 UTC |
DUFFY MICHAEL PSee Remarks
|
Exercise / conversionStock Option (right to buy) · Derivative | 27,313 | $0.00 Strike: $5.62 | $0.00 |
DisclosureSEC source: 0000899243-18-009569 · doc4.xml · derivative · entry 3 DUFFY MICHAEL P · CIK 0001237200 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,313 shares Expires 2018-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2017. F3 · derivative.exercise_date: These options were originally granted on April 4, 2008, and originally provided for vesting based on the level of LNTH's satisfaction of certain performance criteria for each of fiscal years 2009, 2010, 2011 and 2012. As previously reported on a Form 4 filed with the SEC on June 25, 2015, these options were amended in connection with LNTH's initial public offering on June 25, 2015 to provide for additional vesting on the third anniversary of the amendment date (or the day before any earlier expiration) of any options that remain unvested at that time. As a result, these options became exercisable on April 3, 2018, one day prior to their expiration on April 4, 2018. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:23 UTC |
DUFFY MICHAEL PSee Remarks
|
SaleCommon Stock | 27,313 | $15.30 | $417,897.09 |
DisclosureSEC source: 0000899243-18-009569 · doc4.xml · nonDerivative · entry 2 DUFFY MICHAEL P · CIK 0001237200 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,159 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.05 to $15.65, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:23 UTC |
DUFFY MICHAEL PSee Remarks
|
Exercise / conversionCommon Stock | 27,313 | $5.62 | $153,499.06 |
DisclosureSEC source: 0000899243-18-009569 · doc4.xml · nonDerivative · entry 1 DUFFY MICHAEL P · CIK 0001237200 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2017. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 16:10 UTC |
DUFFY MICHAEL PSee Remarks
|
SaleCommon Stock | 11,492 | $16.60 | $190,775.24 |
DisclosureSEC source: 0000899243-18-007705 · doc4.xml · nonDerivative · entry 1 DUFFY MICHAEL P · CIK 0001237200 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,159 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.35 to $16.825, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 16:32 UTC |
SCHAFFER DERACE LDirector
|
GrantCommon Stock | 7,911 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006646 · doc4.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,641 Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 16:30 UTC |
Pruden Gary JDirector
|
GrantCommon Stock | 7,911 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006640 · doc4.xml · nonDerivative · entry 1 Pruden Gary J · CIK 0001673416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,911 Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:43 UTC |
McHugh JulieDirector
|
GrantCommon Stock | 7,911 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006657 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,312 Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:35 UTC |
Clemmer James CDirector
|
GrantCommon Stock | 7,911 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006651 · doc4.xml · nonDerivative · entry 1 Clemmer James C · CIK 0001476700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,634 Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 16:35 UTC |
Thrall James HDirector
|
GrantCommon Stock | 7,911 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006650 · doc4.xml · nonDerivative · entry 1 Thrall James H · CIK 0001315048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,911 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.